Premium
Overexpression of the VAV proto‐oncogene product is associated with B‐cell chronic lymphocytic leukaemia displaying loss on 13q
Author(s) -
PrietoSánchez Rosario M.,
Hernández José A.,
García Juan L.,
Gutiérrez Norma C.,
Miguel Jesús San,
Bustelo Xosé R.,
Hernández Jesús M.
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06094.x
Subject(s) - chronic lymphocytic leukemia , b cell , lymphoma , oncogene , cancer research , medicine , immunology , biology , cell cycle , leukemia , cancer , antibody
Summary The expression of the VAV proto‐oncogene in 57 patients with chronic myeloproliferative disease (CMD), B‐cell acute lymphoblastic leukaemia (B‐ALL) and B‐cell non‐Hodgkin Lymphoma (B‐NHL), and 61 with B‐cell chronic lymphocytic leukaemia (B‐CLL) was analysed. VAV overexpression was observed in 19·5% of cases and 81% of VAV‐positive tumours also displayed VAV phosphorylation. Overexpression was not observed in B‐ALL or CMD, but 13% of B‐NHL and 34·4% of B‐CLL patients ( P = 0·002) overexpressed VAV. The overexpression and phosphorylation of VAV was detected more frequently in 13q‐ chronic lymphocytic leukaemias (71.4%) versus other B‐CLLs (23·4%, P = 0·001). Overexpression of VAV protein is a frequent event in patients with B‐CLL displaying loss of 13q sequences.